Darwin Wealth Management LLC Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Darwin Wealth Management LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 36.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 587 shares of the medical research company’s stock after acquiring an additional 158 shares during the quarter. Darwin Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $305,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Thermo Fisher Scientific by 2.1% in the first quarter. BlackRock Inc. now owns 31,423,285 shares of the medical research company’s stock valued at $18,111,439,000 after acquiring an additional 633,163 shares in the last quarter. Morgan Stanley lifted its position in shares of Thermo Fisher Scientific by 17.7% during the fourth quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock worth $6,459,629,000 after purchasing an additional 1,764,312 shares during the last quarter. FMR LLC increased its holdings in Thermo Fisher Scientific by 1.7% in the first quarter. FMR LLC now owns 11,354,044 shares of the medical research company’s stock valued at $6,544,130,000 after buying an additional 194,602 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Thermo Fisher Scientific by 1.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,123,657 shares of the medical research company’s stock valued at $5,024,306,000 after buying an additional 161,344 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC grew its position in shares of Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after acquiring an additional 8,347,260 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. Barclays raised their price objective on Thermo Fisher Scientific from $590.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. KeyCorp decreased their price target on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a report on Thursday, May 25th. Wells Fargo & Company raised their target price on shares of Thermo Fisher Scientific from $505.00 to $520.00 and gave the stock an “underweight” rating in a report on Friday, July 28th. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Wednesday, September 6th. They set a “buy” rating and a $625.00 target price for the company. Finally, JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $660.00 to $670.00 in a report on Thursday, July 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $631.71.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $507.95 on Tuesday. The firm has a market capitalization of $196.04 billion, a price-to-earnings ratio of 34.72, a price-to-earnings-growth ratio of 2.43 and a beta of 0.77. The stock’s fifty day moving average is $540.37 and its 200-day moving average is $541.53. Thermo Fisher Scientific Inc. has a one year low of $475.77 and a one year high of $609.85. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.42.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $5.15 EPS for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). Thermo Fisher Scientific had a return on equity of 18.59% and a net margin of 13.14%. The company had revenue of $10.69 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the firm posted $5.51 earnings per share. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 22.37 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be given a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.57%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 1,600 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $550.60, for a total value of $880,960.00. Following the sale, the chief executive officer now directly owns 135,330 shares in the company, valued at $74,512,698. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 3,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total value of $1,673,310.00. Following the transaction, the executive vice president now owns 17,556 shares in the company, valued at $9,792,210.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 1,600 shares of the stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $550.60, for a total value of $880,960.00. Following the sale, the chief executive officer now owns 135,330 shares of the company’s stock, valued at approximately $74,512,698. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock worth $15,799,270 over the last 90 days. 0.32% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.